(CTN News) – Over 40 percent of stomach cancer cases in China are caused by the infection of Helicobacter pylori, also referred to as HP.
According to the nation’s first white paper on HP infection prevention and control in China, there is a stomach cancer prevalence of HP infection among Chinese individuals of about 56 percent, along with a family-based infection rate of 71 percent.
According to statistics, China currently faces a heavy burden of stomach cancer, with the disease accounting for the 4th most common incidence and the third most common cause of death of all cancers.
According to the American Cancer Society, stomach cancer accounts for 12.4 percent of all the cancer related deaths in the country.
As a result of infecting the stomach with bacteria, HP infection occurs as a result of infecting the stomach with bacteria. Generally, this occurs during the early years of a child’s life. There is a strong correlation between obesity and stomach ulcers, gastritis, and stomach cancer.
Several points were made in the white paper regarding the importance of receiving a proper diagnosis and treatment for HP infection, as well as the importance of eradicating the disease from the patient’s body.
It is recommended that when HP infections are detected, they should be treated as soon as possible so that further complications can be avoided as soon as possible.
There is no doubt that HP eradication is the most important and first-line measure for the prevention and control of stomach cancer that medical experts recommend. The risk of cancer can be reduced by 52 percent when you take this medication.
There are more innovative medicines available today compared to conventional medications, which are less likely to cause side effects and have a better eradication effect than traditional medications.
It is expected that the China International Import Expo, which is held every year in Shanghai, will feature a number of innovative medicines this year.
After its new application for HP stomach cancer eradication indication was approved by the Chinese authority earlier this year, the pharmaceutical company Takeda has announced it will bring its vonoprazan fumarate tablet to this year’s CIIE.
As a result of the cancer CIIE, the company expressed its deep gratitude to the Chinese government for enhancing its ability to introduce new drugs to the Chinese market.